Navigation Links
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Date:12/18/2007

LEXINGTON, Mass., Dec. 18 /PRNewswire/ -- ActivBiotics, Inc. today announced that following a review of strategic options after its clinical trial of Rifalazil failed in peripheral arterial disease patients, the Company is selling all or substantially all of its assets on an "as is" basis through an Assignment for the Benefit of Creditors, process. The Assignee of the assets is Mr. Joseph Finn, Jr., CPA (see contact details below). The bidding for the assets, which may be purchased separately or in combination, will begin today and end on February 1, 2008. Any person interested in purchasing the assets or learning more about the bidding process should contact the Assignee, Mr. Joseph Finn, Jr.

"The Board of Directors has decided to pursue the sale of the company's clinical and preclinical drug assets," said Steven C. Gilman, Ph.D., Chairman of ActivBiotics. "We believe that our anti-inflammatory Phase II drug candidate and our antibacterial library of compounds are of significant value to companies in those therapeutic areas," added Gilman. Bidding packages have been assembled and are ready to be distributed subject to a potential purchaser entering into a standard form confidentiality agreement.

The Company assets available for sale include:

1. A superoxide dismutase (SOD) mimetic program consisting of two clinical-stage drug candidates, M40403 and M40419, and a library of 250 small molecules which have potential as novel therapeutic agents for the treatment of inflammatory diseases. M40403, which has been studied in approximately 700 patients/subjects, has an active IND, and a protocol on file with the FDA under which a Phase II clinical trial for the treatment of post-operative ileus can be conducted, and a protocol to initiate a Phase II clinical trial for the treatment of oral mucositis. The Company has submitted and expects to shortly receive Orphan Drug Designation status in Europe and has an Orphan Drug application pending with the US FDA for the treatment of oral mucositis in subjects with advanced head and neck cancer. In addition to these indications, the SOD mimetics have potential therapeutic uses in a variety of inflammatory disorders including asthma, chronic obstructive pulmonary disease, and radiation protection, stroke, and ischemia reperfusion injury.

2. An antibacterial library of compounds consisting of approximately 800 small molecules, all new chemical entities (NCEs), which may be developed for the treatment of serious bacterial infections, including complicated skin and skin structure infections, endocarditis, osteomyelitis, foreign-body infections, Clostridium difficile-associated diarrhea (CDAD), as well as peptic ulcer disease due to Helicobacter pylori, and disease due to Chlamydia infections. In addition, these NCEs have the potential to be administered as topical agents for the treatment of acne and for the eradication of Staphylococcus aureus in nasal passages.

3. Rifalazil, a clinical stage compound which has been tested in approximately 600 patients, is a potent antibacterial agent with activity mainly against pathogenic Gram-positive bacteria. Rifalazil was found efficacious in a Phase II Chlamydia STD clinical trial, and, separately, a protocol has been submitted to the FDA to begin a Phase II clinical trial in carotid artery atherosclerosis. Rifalazil has been granted Fast Track designation for the treatment of CDAD. The Company has open INDs to continue rifalazil development for infectious diseases, and atherosclerosis-related disease.

Request for Further Information

Interested parties can obtain a bidder's package by contacting Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. The package is intended to provide prospective purchasers with information concerning the Company's Sale of Assets and conveyancing documents. For technical information or questions regarding the products all such inquiries shall be directed to Christo Shalish, cshalish@activbiotics.com, and/or Glenn Kazo, gkazo@activbiotics.com.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates" or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. ActivBiotics, Inc. will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Exelixis Sells 80% Stake in Artemis to Taconic
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network ... and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... DUBLIN , Feb. 10, 2016  Allergan plc ... today announced that Brent Saunders , Allergan,s CEO ... in a fireside chat session at the RBC Capital ... 12:30 p.m. ET at The New York Palace Hotel ... presentation will be webcast live and can be accessed ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
Breaking Biology News(10 mins):